Green Plains Partners LP

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

Square Peg Communications and VIAVI Solutions Join Forces to Advance 5G NTN Testing

Iridium Introduces NTN Direct Service: Will the Stock Benefit?

Green Plains Inc. Completes Acquisition of Green Plains Partners LP

Green Plains Inc. and Green Plains Partners LP Announce Unitholder Approval of Merger

Green Plains Partners: Can Its Nearly 14% Dividend Yield Be Sustainable?

Green Plains Partners LP (GPP) Q3 2023 Earnings Call Transcript

Green Plains Partners Reports Third Quarter 2023 Financial Results

Green Plains Partners Announces Quarterly Distribution

Green Plains to Host Third Quarter 2023 Earnings Conference Call on October 31, 2023

Shareholder Alert: Ademi LLP investigates whether Green Plains Partners LP has obtained a Fair Price in its transaction with Green Plains Inc.

Why Shares of Green Plains Partners Just Hit a 52-Week High

Green Plains Inc. and Green Plains Partners LP Announce Definitive Merger Agreement

Green Plains Partners Reports Second Quarter 2023 Financial Results

Green Plains Partners Announces Quarterly Distribution

Green Plains to Host Second Quarter 2023 Earnings Conference Call on August 4, 2023

Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial

Green Plains Partners: Growing Volumes Benefiting The High Yield

Green Plains Announces Offer to Acquire Green Plains Partners LP